SCHEMBL4189116

SCHEMBL4189116

CC(C)(C)[Si](C)(C)O[C@H]1C(=O)N[C@H]1c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
P2RX7 Q99572 3/20 0.34
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
CA2 P00918 1/20 0.33
BUB1 O43683 1/20 0.32
GAA P10253 2/20 0.31
LMNA P02545 1/20 0.31
PTGS2 P35354 1/20 0.31
THRB P10828 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
GFER P55789 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9375970 1.00 CYP2D6 (0.35) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7
SCHEMBL3074342 0.84 CYP2D6 (0.38) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7
SCHEMBL3074348 0.84 CYP2D6 (0.38) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7
SCHEMBL3074344 0.84 CYP2D6 (0.38) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7
SCHEMBL6332675 0.77 MEN1 (0.41) CYP2D6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL5963643 0.77 KMT2A (0.36) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7
SCHEMBL3088041 0.77 MEN1 (0.41) CYP2D6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3088031 0.77 MEN1 (0.41) CYP2D6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3088036 0.77 MEN1 (0.41) CYP2D6KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL20640923 0.75 SMN1; SMN2 (0.35) CYP2D6KMT2AMEN1SMN1; SMN2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure DAIICHI SANKYO COMPANY LIMITED (JP) 2009-07-23 US disclosed
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure DAIICHI SANKYO COMPANY LIMITED (JP) 2009-07-23 US disclosed
EP-1942109-A1 TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE Daiichi Sankyo Company, Limited (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure ABCC1, AZI2, TPD52L2 CYP2D6 904/4885KMT2A 950/4885MEN1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.